GlassScriptPhysician profile
Judith Marie Hackett
NPI 1487610598
$1,432.16
in general payments reported to CMS, 2019-2025
13 companies · $213 in 2025
The $213 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $59.07 · 2020: $257 · 2021: $339 · 2022: $133 · 2023: $106 · 2024: $325 · 2025: $213.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $644.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $644.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $504.17 | 2020-2024 | Airsupra, Fasenra |
| Abbvie INC. | $209.96 | 2021-2023 | |
| Glaxosmithkline, LLC. | $142.39 | 2019-2023 | Trelegy Ellipta, Shingrix, Arexvy |
| Acadia Pharmaceuticals INC | $113.44 | 2025 | Nuplazid |
| Gilead Sciences, INC. | $110.50 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $99.91 | 2025 | Austedo Xr |
| Lilly USA, LLC | $76.99 | 2020-2022 | |
| Sunovion Pharmaceuticals INC. | $68.08 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $40.13 | 2022 | |
| Novartis Pharmaceuticals Corporation | $19.18 | 2019 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $18.34 | 2024 | Caplyta |
| Janssen Biotech, INC. | $17.89 | 2023 | Tremfya |
| Allergan, INC. | $11.18 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Judith Hackett listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.